CBD reduced schizophrenia-like symptoms in an animal model through two identified pathways: dampening neuroinflammation and modulating serotonin-MAPK signaling—providing a mechanistic basis for CBD's potential antipsychotic effects.
Psychiatric pharmacologists, schizophrenia researchers, and CBD scientists interested in antipsychotic mechanisms.
What the researchers found
RTHC-00193 reviewed clinical evidence that CBD may have therapeutic potential for schizophrenia. This study investigates the how—using network pharmacology to predict CBD's targets and then validating those predictions in both cell cultures and a ketamine-induced animal model of schizophrenia.
The computational analysis (network pharmacology) identified neuroinflammation and 5-HT1A receptor-MAPK signaling as promising pathways. The experimental work confirmed both.
In cell cultures, CBD significantly reduced pro-inflammatory markers (NO, IL-1β, IL-6, TNF-α) and modulated the serotonin 5-HT1A receptor-MAPK pathway—increasing 5-HT1A receptor expression while decreasing MAPK/ERK1/2 phosphorylation.
In the animal model, CBD alleviated multiple schizophrenia-like symptoms after just 5 consecutive days of treatment: reduced anxiety (confirmed in two different behavioral tests), improved spatial memory (Y-maze), and improved social behavior. Critically, the researchers validated that CBD's effects depended on the specific 5-HT1AR-MAPK pathway predicted by the network analysis.
The dual mechanism—anti-inflammatory plus serotonin modulation—is important because schizophrenia involves both neuroinflammation and serotonin dysregulation. A treatment that addresses both simultaneously could be more effective than current antipsychotics, which primarily target dopamine.
Why it matters
Current antipsychotics have significant side effects (weight gain, metabolic syndrome, movement disorders) and limited efficacy for negative and cognitive symptoms. CBD's dual mechanism—targeting both inflammation and serotonin signaling—could address dimensions of schizophrenia that current treatments miss, with a potentially better side effect profile.
The numbers in context
CBD reduced: NO, IL-1β, IL-6, TNF-α (p < 0.05). Increased 5-HT1AR expression, decreased MAPK/ERK1/2 phosphorylation (p < 0.05). Behavioral improvements: anxiety (p < 0.01 in two tests), spatial memory (p < 0.01), social behavior (p < 0.0001). 5 days of treatment.
How the study worked
Network pharmacology to predict CBD targets and pathways in schizophrenia. In vitro: CBD (10 mg/kg, i.p.) effects on pro-inflammatory cytokines and 5-HT1AR-MAPK signaling in LPS-induced neuroinflammation model. In vivo: CBD in ketamine-induced schizophrenia model in animals; behavioral tests (open field, elevated plus maze, Y-maze, social interaction) after 5 days of treatment.
Who was studied
Mice (C57BL strain) used in a ketamine-induced model of schizophrenia.
What this study cannot tell us
Animal model of schizophrenia (ketamine-induced) is a simplified approximation of a complex human disease. Network pharmacology predicts but doesn't prove mechanism in humans. The 5-day treatment period is very short compared to the chronic treatment schizophrenia requires. CBD dose used may not be achievable orally in humans due to bioavailability issues. In vitro and in vivo doses may not translate to human therapeutic ranges.
How to read the evidence
Preclinical study combining computational prediction with in vitro and in vivo validation—mechanistically strong but requiring human translation.
When this study was published
Published in 2025, using network pharmacology to bridge computational and experimental approaches.
The bigger picture
This provides the mechanistic foundation for the clinical observations in RTHC-00193 (CBD's potential therapeutic effects in schizophrenia). It also connects to RTHC-00184's review of CBD's immunomodulatory properties—the anti-inflammatory mechanism identified here for schizophrenia specifically overlaps with CBD's broader immune effects. The serotonin pathway adds a dimension that wasn't captured in the immunology-focused review, showing CBD operates on multiple neurotransmitter systems simultaneously.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Will CBD show antipsychotic effects in human clinical trials large enough to be definitive? Could CBD be combined with low-dose conventional antipsychotics for enhanced efficacy? Does CBD's dual mechanism predict better outcomes for patients with both inflammatory and serotonin-related symptom profiles?
Read the original research
Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation.
Molecular neurobiology, 63(1), 278
Molecular Neurobiology publishes high-quality research on the molecular basis of neurological and psychiatric disorders.
Citation
Wei, Ying; Liu, Xiang; Lin, Shijun; Jia, Zhiwei; Liu, Lin; Wang, Baiqiang; Liao, Linchuan; Mei, Xue. (2025). Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation.. Molecular neurobiology, 63(1), 278. https://doi.org/10.1007/s12035-025-05608-8
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- THC and Studying: What the Research Says About Cannabis and Learning
- THC and Antipsychotics: A Complicated Relationship
- Cannabis and Multiple Sclerosis: Spasticity, Pain, and the Sativex Story